Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2020

Aug 14, 2020

SELL
$16.86 - $23.44 $30,348 - $42,192
-1,800 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$14.47 - $27.96 $505,003 - $975,804
-34,900 Reduced 95.1%
1,800 $32,000
Q4 2019

Feb 14, 2020

BUY
$15.87 - $23.12 $44,436 - $64,736
2,800 Added 8.26%
36,700 $792,000
Q3 2019

Nov 14, 2019

BUY
$16.91 - $36.27 $52,421 - $112,437
3,100 Added 10.06%
33,900 $617,000
Q2 2019

Aug 14, 2019

BUY
$31.0 - $36.3 $58,900 - $68,970
1,900 Added 6.57%
30,800 $1.1 Million
Q1 2019

May 15, 2019

BUY
$31.58 - $46.35 $227,376 - $333,720
7,200 Added 33.18%
28,900 $971,000
Q4 2018

Feb 14, 2019

BUY
$30.43 - $56.65 $118,677 - $220,935
3,900 Added 21.91%
21,700 $713,000
Q3 2018

Nov 14, 2018

BUY
$46.46 - $68.49 $826,988 - $1.22 Million
17,800 New
17,800 $1.09 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $174M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Capstone Investment Advisors, LLC Portfolio

Follow Capstone Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Capstone Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Capstone Investment Advisors, LLC with notifications on news.